Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Optimizing biologically targeted clinical trials for neurofibromatosis.

Gutmann DH, Blakeley JO, Korf BR, Packer RJ.

Expert Opin Investig Drugs. 2013 Apr;22(4):443-62. doi: 10.1517/13543784.2013.772979. Epub 2013 Feb 21. Review.

2.

Neurofibromatosis-related tumors: emerging biology and therapies.

Karajannis MA, Ferner RE.

Curr Opin Pediatr. 2015 Feb;27(1):26-33. doi: 10.1097/MOP.0000000000000169. Review.

3.

The genetic and molecular pathogenesis of NF1 and NF2.

Yohay KH.

Semin Pediatr Neurol. 2006 Mar;13(1):21-6. Review.

PMID:
16818172
4.

Tumorigenesis in neurofibromatosis: new insights and potential therapies.

Reed N, Gutmann DH.

Trends Mol Med. 2001 Apr;7(4):157-62. Review.

PMID:
11286939
5.

Neurofibromatosis.

McClatchey AI.

Annu Rev Pathol. 2007;2:191-216. Review.

PMID:
18039098
6.

Advances in the treatment of neurofibromatosis-associated tumours.

Lin AL, Gutmann DH.

Nat Rev Clin Oncol. 2013 Nov;10(11):616-24. doi: 10.1038/nrclinonc.2013.144. Epub 2013 Aug 13. Review.

PMID:
23939548
7.

Mouse models of neurofibromatosis 1 and 2.

Gutmann DH, Giovannini M.

Neoplasia. 2002 Jul-Aug;4(4):279-90.

8.

CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.

Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW, Dombi E, Evans GD, Ferner R, Fernandez-Valle C, Fisher MJ, Giovannini M, Gutmann DH, Hanemann CO, Hennigan R, Huson S, Ingram D, Kissil J, Korf BR, Legius E, Packer RJ, McClatchey AI, McCormick F, North K, Pehrsson M, Plotkin SR, Ramesh V, Ratner N, Schirmer S, Sherman L, Schorry E, Stevenson D, Stewart DR, Ullrich N, Bakker AC, Morrison H.

Am J Med Genet A. 2014 Mar;164A(3):563-78. doi: 10.1002/ajmg.a.36312. Epub 2014 Jan 17.

9.

The motor protein kinesin-1 links neurofibromin and merlin in a common cellular pathway of neurofibromatosis.

Hakimi MA, Speicher DW, Shiekhattar R.

J Biol Chem. 2002 Oct 4;277(40):36909-12. Epub 2002 Aug 20.

10.

The neurofibromatoses: when less is more.

Gutmann DH.

Hum Mol Genet. 2001 Apr;10(7):747-55. Review.

PMID:
11257108
11.

New insights into the neurofibromatoses.

Gutmann DH.

Curr Opin Neurol. 1994 Apr;7(2):166-71. Review.

PMID:
8019663
12.

Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.

Blakeley JO, Plotkin SR.

Neuro Oncol. 2016 May;18(5):624-38. doi: 10.1093/neuonc/nov200. Epub 2016 Feb 6. Review.

13.

Neurofibromatosis.

Gerber PA, Antal AS, Neumann NJ, Homey B, Matuschek C, Peiper M, Budach W, Bölke E.

Eur J Med Res. 2009 Mar 17;14(3):102-5. Review.

14.

Neurofibromatosis and associated tumour suppressor genes.

Zwarthoff EC.

Pathol Res Pract. 1996 Jul;192(7):647-57. Review.

PMID:
8880865
15.

[Neurofibromatosis].

Wolkenstein P, Decq P.

Neurochirurgie. 1998 Nov;44(4):267-72. Review. French.

PMID:
9864698
16.

Nosological considerations of the neurofibromatoses.

Viskochil D, Carey JC.

J Dermatol. 1992 Nov;19(11):873-80.

PMID:
1293176
17.

Evaluation of NF2 and NF1 tumor suppressor genes in distinctive gastrointestinal nerve sheath tumors traditionally diagnosed as benign schwannomas: s study of 20 cases.

Lasota J, Wasag B, Dansonka-Mieszkowska A, Karcz D, Millward CL, Ryś J, Stachura J, Sobin LH, Miettinen M.

Lab Invest. 2003 Sep;83(9):1361-71.

PMID:
13679444
18.

[Neurofibromatosis: the most frequent hereditary tumor predisposition syndrome].

Wimmer K.

Wien Med Wochenschr. 2005 Jun;155(11-12):273-80. German.

PMID:
16035388
19.

Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective.

Ferner RE.

Lancet Neurol. 2007 Apr;6(4):340-51. Review.

PMID:
17362838
20.

A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.

Hirokawa Y, Tikoo A, Huynh J, Utermark T, Hanemann CO, Giovannini M, Xiao GH, Testa JR, Wood J, Maruta H.

Cancer J. 2004 Jan-Feb;10(1):20-6.

PMID:
15000491

Supplemental Content

Support Center